AnanianPresident of Direct Response Medicine LLC

Coxin the mid-1980s."Other ablation companies have altered the Maze procedure to meet thelimitations of their energy source.Using the ATS CryoMaze(TM) CryoablationSystem, which can perform all the lesions of the original Maze-III procedure,ATS intends to preserve the original clinical results of that procedure whilesimplifying the access and adoptability.This advisory board represents theablation experts who can provide ATS direction, train other surgeons to repeatthe procedure and obtain optimal clinical results," commented Dr Cox.About ATS MedicalATS Medical, Inc. is dedicated to 'Advancing The Standards' of cardiacsurgery through the development, manufacturing and marketing of innovativeproducts and services for the treatment of structural heart disease. ATSMedical serves the cardiac surgery community by focusing on two distinct butoperationally synergistic market segments: heart valve disease therapy andsurgical ablation of cardiac arrhythmias.ATS was originally founded to develop the ATS Open Pivot(R) Heart Valve asa new mechanical heart valve standard of care. Today the Open Pivot heartvalve is the preferred mechanical heart valve in many markets around the worldand the fastest growing mechanical prosthesis in the market. Building on thislegacy and addressing the largest market segment in heart valve therapy, theATS 3f(R) brand encompasses an innovative tissue heart valve portfolio toaddress conventional open surgery requirements as well as the growing demandfor less invasive sutureless based procedures. The ATS 3f(R) portfolioincludes offerings at various stages including early product development,pivotal clinical trials, and market commercialization.

Completing theportfolio in heart valve therapy is the ATS Simulus(R) annuloplasty productline. Continuing ATS Medical's focuson serving the cardiac surgery community are the ATS CryoMaze(TM) products forsurgical cryoablation of cardiac arrhythmias.ATS CryoMaze(TM) products areused by surgeons to treat patients suffering from cardiac arrhythmias, thelargest and fastest growing form of structural heart disease in populationsover 60 years of age.The ATS Medical web site is http:// HarborThis Press Release contains forward-looking statements that may includestatements regarding intent, belief or current expectations of the Company andits management. Actual results could differ materially from those projected inthe forward-looking statements as a result of a number of important factors,including the results of clinical trials, the timing of regulatory approvals,the integration of 3f Therapeutics and the surgical cryoablation business ofCryoCath Technologies, Inc., regulatory actions, competition, pricingpressures, supplier actions and management of growth. For a discussion ofthese and other risks and uncertainties that could affect the Company'sactivities and results, please refer to the Company's filings with theSecurities and Exchange Commission, including its Form 10-K for the year endedDecember 31, 2007 and its most recent quarterly report on Form 10-Q.SOURCEATS Medical, Inc.Michael Dale, PresidentCEO, 1-763-553-7736, or Michael Kramer, CFO,1-763-557-2222, both of ATS; or Investors, Parice Halbert, CFA of WestwickePartners, LLC, 1-443-213-0500, for ATS.

CHICAGO & TEMECULA, Calif.(Business Wire)CytoCore, Inc. (OTCBB:CYTO), the developer of cost effective products used forthe detection of cancerous and precancerous conditions and privately held ZycomTouch, LLC., today announced that they have reached an agreement in principlefor CytoCore to distribute OmniDROP on an exclusive basis to medicallaboratories, hospitals, and HMO networks in the U.S and non-exclusivelyinternationally. OmniDROP is the first bi-directional HIPAA-compliant peer-to-peer drop boxcommunications software utility for Windows and Apple systems and isspecifically designed to facilitate effective communications between physicians,medical laboratories, healthcare facilities, third party payors and patients.The program is offered on a subscription or fee-for-service basis depending uponthe type of installation. OmniDROP is also designed to support the RingCommunicator, a unique touch-enabled interface that organizes, manages andfacilitates the complex communications inherent in many types of medical anddental procedures. CytoCore will offer OmniDROP as the HIPAA-compliantcommunications network for its Automated Imaging Proteomic Systems (AIPS)Cytology Workstation as well as for communications between physicians, medicallaboratories and healthcare facilities.

"We are pleased to select CytoCore as Zycoms exclusive United States partnerfor the market launch of OmniDROP for laboratories, hospitals and HMOs in theUnited States. OmniDROP and the Ring Communicator will provide excellentcommunication features to the specimen screening, slide reporting and datamanagement capabilities of CytoCores AIPS system," stated John A. Ananian,President of Direct Response Medicine, LLC., the software developer andtechnology licensor to Zycom Touch, LLC. "We believe CytoCores medical systemsindustry experience will be integral to the adoption of our products within thehealthcare chain of providers (physicians, laboratories, hospitals) and payors.Our combined products should dramatically lower provider expenses and increaseoperating efficiencies through reduction of paperwork and redundant operatingprocedures," added Mr Ananian. "CytoCores AIPS workstation documentation management software in conjunctionwith Zycoms OmniDROP and Ring Communicator will offer an effectivecommunication tool for medical providers to meet the healthcare 'paper less'goals of the Obama Administration," stated Robert McCullough, Jr., CytoCoresCEO.